OPKO Health, Inc. (NASDAQ:OPK) Short Interest Update

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 34,960,000 shares, a decrease of 70.0% from the March 31st total of 116,490,000 shares. Currently, 11.5% of the company's stock are sold short. Based on an average daily volume of 4,900,000 shares, the short-interest ratio is presently 7.1 days.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 67,434 shares of the firm's stock in a transaction dated Friday, February 28th. The stock was bought at an average price of $1.71 per share, with a total value of $115,312.14. Following the transaction, the chief executive officer now directly owns 213,301,448 shares in the company, valued at approximately $364,745,476.08. The trade was a 0.03 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders purchased 767,434 shares of company stock valued at $1,238,312. Insiders own 49.69% of the company's stock.

Hedge Funds Weigh In On OPKO Health

Several institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in OPKO Health by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company's stock worth $275,000 after purchasing an additional 8,064 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of OPKO Health by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company's stock valued at $560,000 after buying an additional 8,396 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after buying an additional 12,417 shares during the period. Comerica Bank grew its position in OPKO Health by 18.2% during the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company's stock worth $156,000 after buying an additional 16,369 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in OPKO Health by 4.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company's stock worth $670,000 after acquiring an additional 18,571 shares during the period. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Stock Performance

Shares of NASDAQ:OPK traded up $0.04 during trading on Friday, reaching $1.39. 2,922,263 shares of the stock were exchanged, compared to its average volume of 3,881,073. OPKO Health has a 12 month low of $1.15 and a 12 month high of $2.04. The stock has a 50-day moving average price of $1.62 and a 200-day moving average price of $1.57. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The firm has a market cap of $930.10 million, a PE ratio of -7.29 and a beta of 1.42.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The firm had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business's revenue for the quarter was down 13.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.12) earnings per share. Research analysts expect that OPKO Health will post -0.25 EPS for the current fiscal year.

Analysts Set New Price Targets

OPK has been the subject of a number of research analyst reports. JPMorgan Chase & Co. began coverage on OPKO Health in a report on Friday, April 25th. They set a "neutral" rating for the company. HC Wainwright reiterated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research note on Monday, April 7th. Barrington Research restated an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Thursday. Finally, StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, OPKO Health has an average rating of "Moderate Buy" and an average price target of $2.75.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.